临床荟萃
• 专题 • 上一篇 下一篇
出版日期:
发布日期:
通讯作者:
作者简介:
Online:
Published:
Contact:
摘要： 丙型肝炎病毒（HCV）感染是全球性的公共卫生问题之一。清除HCV感染，达到治愈是丙型病毒性肝炎治疗的最主要目标。近年来直接抗病毒药物（DAA）发展迅猛，可以有效清除病毒，而且安全性和耐受性均较好，国际上已广泛用于HCV感染者的治疗。本文就DAA的分类、特点、耐药问题及不同HCV基因型的治疗方案等的研究进展进行概述。
关键词: 丙型肝炎, 肝炎病毒属, 抗病毒药
Abstract: Hepatitis C virus (HCV) infection is one of the global public health problem， and the eradication of infection is the most important goal in HCV therapy. In recent years， directacting antiviral agents(DAA) develop quickly. Due to the better safety and tolerability in therapy for HCV infection， these new agents are used generally in many countries. This review aims at the recent advances of DAA in characteristics， resistance and current optimal management for HCV various genotypes in patients with HCV infections.
Key words: hepatitis C；hepacivirus；antiviral , agents
崔坡，孔丽，赵素贤. 丙型肝炎的直接抗病毒药物[J]. 临床荟萃, doi: 10.3969/j.issn.1004-583X.2016.07.008.
Cui Po， Kong Li， Zhao Suxian. Directacting antiviral agents in hepatitis C virus infection[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2016.07.008.
导出引用管理器 EndNote|Ris|BibTeX
链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.07.008
https://huicui.hebmu.edu.cn/CN/Y2016/V31/I7/727
